Literature DB >> 27335358

Delirium with anticholinergic symptoms after a combination of paliperidone and olanzapine pamoate in a patient known to smoke cannabis: an unfortunate coincidence.

Anja Kokalj1, Nikolina Rijavec1, Rok Tavčar1.   

Abstract

We report a case of delirium with anticholinergic symptoms in a 19-year-old female patient with schizophrenia. On the day the symptoms emerged, the patient received olanzapine long-acting injection and a higher dose of paliperidone. We observed symptoms ranging from confusion to delirium as well as some anticholinergic symptoms. The delirium lasted 24 hours and was managed by intravenous fluid substitution and oral benzodiazepines. Olanzapine pamoate, paliperidone and cannabis are central nervous system (CNS) depressants, and their combination can increase the risks of CNS depression. In this case report, we review the symptoms of delirium in a case of antipsychotic overdose and provide general guidelines for managing these symptoms. We also review possible complications in combined use of cannabis, olanzapine and paliperidone. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27335358      PMCID: PMC4932405          DOI: 10.1136/bcr-2016-214806

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

1.  Olanzapine pamoate - blockbuster or damp squib?

Authors:  D M Taylor
Journal:  Int J Clin Pract       Date:  2009-04       Impact factor: 2.503

2.  Bad trip due to anticholinergic effect of cannabis.

Authors:  Ajish G Mangot
Journal:  Gen Hosp Psychiatry       Date:  2013-07-29       Impact factor: 3.238

3.  Long-acting injectable olanzapine can give rise to a condition consistent with central anticholinergic syndrome.

Authors:  Tor Skomedal; Sigrid Hanem; Terje Dybvik; Stein Opjordsmoen Ilner
Journal:  Tidsskr Nor Laegeforen       Date:  2013-11-12

4.  Altered mental status from olanzapine overdose treated with physostigmine.

Authors:  M Weizberg; M Su; J L Mazzola; S B Bird; D E Brush; E W Boyer
Journal:  Clin Toxicol (Phila)       Date:  2006       Impact factor: 4.467

Review 5.  Paliperidone for schizophrenia.

Authors:  Christian Dolder; Michael Nelson; Zachariah Deyo
Journal:  Am J Health Syst Pharm       Date:  2008-03-01       Impact factor: 2.637

6.  Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.

Authors:  Holland C Detke; David P McDonnell; Elizabeth Brunner; Fangyi Zhao; Sebastian Sorsaburu; Victoria J Stefaniak; Sara A Corya
Journal:  BMC Psychiatry       Date:  2010-06-10       Impact factor: 3.630

7.  Successful management of olanzapine-induced anticholinergic agitation and delirium with a continuous intravenous infusion of physostigmine in a pediatric patient.

Authors:  Stacey Lynn Hail; Adebisi Obafemi; Kurt C Kleinschmidt
Journal:  Clin Toxicol (Phila)       Date:  2013-03       Impact factor: 4.467

Review 8.  Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.

Authors:  Delia Bishara; David Taylor
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Paliperidone: the evidence of its therapeutic value in schizophrenia.

Authors:  Joshua Kantrowitz; Leslie Citrome
Journal:  Core Evid       Date:  2008-07-31

10.  Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.

Authors:  Chris J Bushe; Deborah Falk; Ernie Anand; Marta Casillas; Elena Perrin; Rashna Chhabra-Khanna; Holland C Detke
Journal:  BMC Psychiatry       Date:  2015-04-02       Impact factor: 3.630

View more
  1 in total

1.  Paliperidone Palmitate-Induced Delirium in an Adolescent with Schizophrenia: Case report.

Authors:  Hassan Mirza; Duncan Harding; Naser Al-Balushi
Journal:  Sultan Qaboos Univ Med J       Date:  2018-09-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.